-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naporafenib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naporafenib in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naporafenib in Solid Tumor Drug Details: Naporafenib (LXH-254) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ERAS-601 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ERAS-601 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ERAS-601 in Solid Tumor Drug Details: ERAS-601 is under development for...
-
Product Insights
NewNet Present Value Model: Erasca Inc’s Naporafenibum
Empower your strategies with our Net Present Value Model: Erasca Inc's Naporafenibum report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Erasca Inc’s Naporafenibum
Empower your strategies with our Net Present Value Model: Erasca Inc's Naporafenibum report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Net Present Value Model: Erasca Inc’s ERAS-007
Empower your strategies with our Net Present Value Model: Erasca Inc's ERAS-007 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naporafenib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naporafenib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Naporafenib in Non-Small Cell Lung Cancer Drug Details: Naporafenib (LXH-254)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NP-137 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NP-137 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NP-137 in Pancreatic Ductal Adenocarcinoma Drug Details: NP-137 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avelumab in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avelumab in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avelumab in Squamous Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ADX-097 in Inflammation
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ADX-097 in Inflammation report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ADX-097 in Inflammation Drug Details: ADX-097 is under development for the treatment of...